Dr. Jain is a consultant in neurology and has no relevant financial relationships to disclose.)
Historical note and terminology
Dopamine agonists have been shown to be effective in delaying levodopa-induced dyskinesia in early Parkinson disease, but intermittent administration of short-acting dopaminergic agents can predispose Parkinson disease patients to motor fluctuations. Rotigotine, a non-ergot dopamine D2 agonist, has antiparkinsonian effects when infused intravenously, and a transdermal preparation is now available as rotigotine constant delivery system (CDS), which allows a constant delivery of the drug. This is a significant development in the treatment of Parkinson disease. In addition to an improved safety profile and symptomatic effectiveness, transdermal rotigotine can simplify treatment for physicians as well as patients. It is particularly useful for patients with dysphagia who have difficulty swallowing oral medications. It was approved in the United States by the FDA in 2007.
The content you are trying to view is available only to logged in, current MedLink Neurology subscribers.
If you are a subscriber, please log in.
If you are a former subscriber or have registered before, please log in first and then click select a Service Plan or contact Subscriber Services. Site license users, click the Site License Acces link on the Homepage at an authorized computer.